Association of plasma oligomerized beta amyloid with neurocognitive battery using Korean version of consortium to establish a registry for Alzheimer's disease in health screening population

Jung Ju Lee, Youngki Choi, Soie Chung, Dae Hyun Yoon, Seung Ho Choi, Sung Min Kang, David Seo, Kyung Il Park

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

The increasing prevalence of Alzheimer's disease (AD) has become a global phenomenon presenting serious social and health challenges. For detecting early molecular changes in the disease, several techniques to measure varied species of amyloid beta in the peripheral blood have been recently developed, but the efforts to associate them with cognitive assessments have yet to produce suffcient data. We prospectively collected participants from the consecutive population who visited our center for brain health screening. In total, 97 participants (F:M = 58:39) aged 69.4 ± 7.52 were assessed. Participants performed the Korean version of the Consortium to Establish a Registry for Alzheimer's disease (CERAD-K), the clinical dementia rating (CDR), plasma oligomeric amyloid-β (OAβ) level tests, routine blood tests, ApoE genotype, and brain MRI. Among total population, 55.7% had a CDR of 0, and 40.2% had a CDR of 0.5. The results showed that word memory and word recall, and the total scores of the CERAD-K were negatively correlated with the plasma OAβ level. With a cut-off value of 0.78 ng/mL for the OAβ level and a -1.5 standard deviation of age/sex/education adjusted norms for the CERAD-K; naming, word memory, word recall, word recognition, and total score were significantly correlated with the OAβ level. No correlation between the OAβ level and mini-mental status examination was found. Our results demonstrate that the level of plasma OAβ was well correlated with the measure of cognitive function through the CERAD-K in the field data collected from consecutive populations. Studies on longitudinal comparisons with large cohorts will further validate the diagnostic value of plasma OAβ as a useful biomarker for screening AD and predicting progression.

Original languageEnglish
Article number237
JournalDiagnostics
Volume10
Issue number4
DOIs
StatePublished - Apr 2020

Keywords

  • Alzheimer's disease
  • Amyloid-β protein
  • Blood biomarker
  • CERAD
  • Cognitive assessment
  • Oligomer

Fingerprint Dive into the research topics of 'Association of plasma oligomerized beta amyloid with neurocognitive battery using Korean version of consortium to establish a registry for Alzheimer's disease in health screening population'. Together they form a unique fingerprint.

Cite this